Core Viewpoint - G2 Goldfields Inc. has successfully obtained shareholder approval for the spin-out of its non-core assets into G3 Goldfields Inc., a wholly owned subsidiary, through a plan of arrangement under the Canada Business Corporations Act [1][4]. Voting Results - A total of 190,251,811 G2 Shares were voted, representing approximately 74.03% of all outstanding shares [2]. - The election of directors received significant support, with J. Patrick Sheridan receiving 99.21% approval and Daniel Noone receiving 96.69% [3]. - The approval for the spin-out plan was overwhelmingly supported, with 99.96% of votes cast in favor [3]. Spin-Out Update - The final court hearing for the spin-out approval is scheduled for December 3, 2025, and the completion is expected in Q1 2026, pending regulatory approvals [4]. - G2 will transfer its interests in non-core assets to a Guyanese subsidiary of G3 and provide approximately C$15 million in cash to meet G3's working capital needs [5]. Share Distribution - G2 shareholders will receive one G3 Share for every two G2 Shares held as of the effective date of the spin-out [5]. - Only shareholders of G2 as of the close of business on the effective date will be entitled to receive G3 Shares, with no change in their holdings in G2 as a result of the spin-out [5]. Company Overview - G2 Goldfields focuses on finding and developing gold deposits in Guyana, with a history of discovering over 10 million ounces of gold in the Guiana Shield [7]. - The company announced an updated mineral resource estimate for the Oko property, highlighting significant inferred and indicated gold resources [7][11].

Core Viewpoint - Nyxoah is actively participating in the Piper Sandler 37th Annual Healthcare Conference, showcasing its innovative solutions for Obstructive Sleep Apnea (OSA) treatment [1]. Company Overview - Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for OSA, with its lead product being the Genio system, which is a leadless and battery-free hypoglossal neurostimulation therapy [3]. - The company aims to improve the quality of life for OSA patients, allowing them to enjoy restful nights [3]. Product Development and Regulatory Approvals - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4]. - Nyxoah has completed two successful IPOs, one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021 [4]. - The company expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients after positive outcomes from the BETTER SLEEP study, which are currently contraindicated in competitors' therapies [4]. - Nyxoah announced positive results from the DREAM IDE pivotal study and received FDA approval for a subset of adult patients with moderate to severe OSA, specifically those with an Apnea-Hypopnea Index (AHI) of 15 to 65 [4].

Core Viewpoint - Quantum BioPharma Ltd. is involved in a significant legal battle against CIBC and RBC, alleging stock market manipulation through "stock spoofing," with a lawsuit amounting to USD $700 million [2][4]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [5]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is linked to its product unbuzzd™, and has a royalty agreement that could yield up to $250 million [5]. Legal Context - The ongoing lawsuit against CIBC and RBC is based on allegations that these banks facilitated stock spoofing, with claims that over 16 million illegal orders were placed through their platforms [4]. - The investigative series by CTV News highlights the broader implications of stock spoofing on retail investors and the integrity of the market [2][4].

Core Insights - Vow ASA's primary insiders have made significant share purchases, indicating confidence in the company's future performance [1] Insider Transactions - Thomas Fredrick Borgen, chair of the board, purchased 300,000 shares [1] - Tbfconsulting AS, associated with Thomas Fredrick Borgen, acquired 81,101 shares [1] - Egil Haugsdal, board member, bought 200,000 shares [1] - Cecilie Brænd Hekneby, CFO, purchased 1,140,000 shares [1] - Ulf Tore Hekneby, a close associate of the CFO, acquired 771,000 shares [1] - Ulrik Hekneby, another close associate of the CFO, purchased 65,000 shares [1]

Core Points - Air Canada has launched a special livery to honor Canadian Olympians and Paralympians for the Milano Cortina 2026 Games, featuring images of Team Air Canada Athlete Ambassadors on an Airbus A330 [1][5] - As the Official Airline of Team Canada, Air Canada will transport over 750 athletes and delegation members to and from the Games, ensuring a seamless travel experience through its employee-driven Going for Gold program [3][5] - The new livery symbolizes the strength and dedication of Canadian athletes, reflecting Air Canada's long-standing support for Team Canada since 1988 for the Olympic Team and 2007 for the Paralympic Team [4][6] Company Overview - Air Canada is the largest airline in Canada and a founding member of Star Alliance, providing scheduled service to over 180 airports globally [7] - The airline's Aeroplan program is Canada's premier travel loyalty program, allowing members to earn or redeem points across a vast network of airline partners and other services [7] - Air Canada aims for net-zero greenhouse gas emissions by 2050 as part of its climate-related ambitions [7]

Group 1 - The resignation of a non-executive director has been accepted by Banco Comercial Português, S.A. [1] - The company has proceeded with the co-optation of a new non-executive director following the resignation [1]

Group 1 - The core message from Stella Li of BYD emphasizes confidence in the performance of the ATTO 2 DM-i, claiming it will outperform competitors in the market [1] - The company is positioning the ATTO 2 DM-i as a leading model in the electric vehicle segment, aiming to capture significant market share [1] Group 2 - BYD's strategy includes leveraging advanced technology and innovative features in the ATTO 2 DM-i to attract consumers [1] - The company is focused on enhancing its competitive edge through continuous improvement and adaptation to market demands [1]

Banco Comercial Português, S.A. informs on 9M 2025 Report and Accounts Attachment RCBCP9M 2025EN ...

Core Insights - Vallourec has received Investment Grade ratings from Moody's, S&P Global, and Fitch, indicating robust financial health and improved cash generation capabilities [1][2][6] Group 1: Credit Ratings - Moody's upgraded Vallourec's issuer rating from Ba1 to Baa3, reflecting successful strategic transformation and cost reduction since 2022 [1][6] - S&P Global upgraded Vallourec's long- and short-term issuer credit ratings from BB+/B to BBB-/A-3, citing sustainable margin improvements and resilience despite macroeconomic uncertainties [1][6] Group 2: Strategic Outlook - The company anticipates continued cash conversion improvement as restructuring costs decrease, supporting profitable growth [2] - Investment Grade status enhances Vallourec's flexibility in optimizing its balance sheet and accessing debt capital markets under favorable conditions [2] Group 3: Company Overview - Vallourec is a leader in premium tubular solutions for energy markets and industrial applications, employing nearly 13,000 people across more than 20 countries [3] - The company focuses on innovative and competitive tubular solutions, catering to demanding environments and projects [3]

Core Insights - GENFIT has appointed Dr. Pejvack Motlagh as the new Chief Medical Officer, who will oversee the company's clinical development strategy and execution [1][2][5] - Dr. Motlagh brings over 20 years of experience in the pharmaceutical and biotechnology sectors, with a strong background in drug development across various therapeutic areas [3][4] - The company focuses on addressing unmet medical needs in rare and life-threatening liver diseases, particularly Acute on-Chronic Liver Failure (ACLF) and related conditions [6][7] Company Overview - GENFIT is a biopharmaceutical company dedicated to improving the lives of patients with rare liver diseases, with a history of over two decades in liver disease research and development [6] - The company is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA, and is listed on the Euronext regulated market [9] - GENFIT's R&D portfolio includes therapeutic assets targeting ACLF, acute decompensation, hepatic encephalopathy, cholangiocarcinoma, urea cycle disorders, and organic acidemias [7] Recent Developments - The appointment of Dr. Motlagh is seen as pivotal for advancing GENFIT's clinical programs, particularly in the context of increasing focus on ACLF within the liver disease community [5] - The company achieved accelerated approval for Iqirvo® (elafibranor) in 2024 for the treatment of Primary Biliary Cholangitis (PBC), which is now marketed in several countries [8] - GENFIT also has a diagnostic franchise, including NIS2+® for detecting Metabolic dysfunction-associated steatohepatitis (MASH) [8]